Simply Wall St.
Did a Hympavzi Trial Death and Tighter Guidance Just Reframe Pfizer's (PFE) Risk–Reward Story?
➖
AI Sentiment
Neutral
4/10
Pfizer Inc. News
Latest updates and market news for PFE
20 news
Dec 19 - Dec 25, 2025
Page 1
Newsfile
Telescope Innovations Reports Significant Milestones and Financial Results of Fiscal Year 2025
📊
AI Sentiment
Positive
7/10
Zacks
Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade
📉
AI Sentiment
Negative
3/10
Zacks
Will the Recent Pricing Deal With the Government Impact BMY's Sales?
📊
AI Sentiment
Positive
6/10
MT Newswires
Pfizer Reports Participant's Death in Hympavzi Extension Study in Hemophilia
➖
AI Sentiment
Neutral
5/10
GuruFocus.com
Pfizer Stock Is Down -- Patient Death in Hemophilia Study Raises Safety Concerns
📉
AI Sentiment
Negative
3/10
Barrons.com
This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%.
📈
AI Sentiment
Highly Positive
9/10
PR Newswire
Flagship Pioneering and Repertoire® Immune Medicines Announce Agreement to Identify T Cell-Targeted Immune Medicines for Prostate Cancer Under Strategic Partnership with Pfizer
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Positive Phase 3 PADCEV–Keytruda Bladder Cancer Data Could Be A Game Changer For Astellas Pharma (TSE:4503)
📊
AI Sentiment
Positive
7/10
Motley Fool
Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?
📉
AI Sentiment
Negative
3/10
Simply Wall St.
Reassessing Astellas Pharma (TSE:4503) Valuation After Positive PADCEV-Keytruda Phase 3 Bladder Cancer Results
📊
AI Sentiment
Positive
7/10
Simply Wall St.
Is Pfizer A Recovery Opportunity After Covid Vaccine Boom Fades?
📊
AI Sentiment
Positive
6/10
Investor's Business Daily
Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump
📊
AI Sentiment
Positive
7/10
Share this news page